Peptide News Digest

#Pacibekitug

2 stories

Industry · View digest

Novartis Reports 4%+ Share Gain Following Tuesday REMODEL RMS Phase 3 Win; Focus Turns to Pacibekitug IL-6 Phase 3 Advance and Avidity RNAi Neuromuscular Integration

Novartis (NYSE: NVS) shares rose more than 4% Tuesday September 1 and continued climbing Wednesday September 2, 2026 following the twin REMODEL-1 and REMODEL-2 Phase 3 wins of remibrutinib (an oral BTK inhibitor) in relapsing multiple sclerosis, which met both primary endpoints versus teriflunomide with a clean liver-safety profile across the 4,500+ patient program. Investor focus now turns to two additional Novartis growth-vehicle programs: pacibekitug (an anti-IL-6 monoclonal antibody acquired in the $1.4 billion Tourmaline Bio acquisition earlier in 2026) advancing into Phase 3 for cardiovascular risk reduction despite Novo Nordisk's ZEUS ziltivekimab Phase 3 miss at ESC 2026 last weekend; and the ongoing integration of the $12 billion Avidity Biosciences acquisition centered on RNAi drug delivery to muscle tissue for facioscapulohumeral muscular dystrophy, DM1 myotonic dystrophy, and Duchenne muscular dystrophy programs. Novartis Q3 2026 earnings release is scheduled for late October.

Industry · View digest

Novartis Reiterates Phase 3 Commitment to Pacibekitug IL-6 Inhibitor Despite Novo Nordisk Ziltivekimab ZEUS Failure; $1.4B Tourmaline Bio Acquisition Backing

Novartis (NYSE: NVS) reiterated at ESC Congress 2026 Saturday August 29 that it will advance the Phase 3 program for pacibekitug (an anti-IL-6 monoclonal antibody acquired from Tourmaline Bio through the $1.4 billion acquisition completed earlier in 2026) for cardiovascular risk reduction in inflammation-driven disease, notwithstanding the Phase 3 ZEUS trial failure of Novo Nordisk's ziltivekimab announced the same weekend. Novartis's stance is that ZEUS was underpowered in the specific ASCVD-plus-CKD-plus-inflammation subgroup rather than a class-level miss for IL-6 blockade, and that pacibekitug's differentiated pharmacokinetic profile (longer half-life and less frequent dosing) plus the differently-selected patient population in the planned Phase 3 will allow the mechanism to prove out. The commitment is a $1.4 billion acquisition-scale bet against the base-rate signal from ZEUS and continues the pattern of large pharma anti-inflammatory cardiovascular pipeline commitment following the earlier successful CANTOS canakinumab (IL-1β) proof of concept.